Senzime Annual Report 2019
Press release: Uppsala, April 16, 2020. Senzime AB (publ) today announces that the company's Annual report for year 2019 is now available in Swedish on the company's website www.senzime.com
For further information, please contact:
Pia Renaudin, CEO of Senzime AB
Tel: +46 (0)70-813 34 17, email: [email protected]
Erik Bergman, CFO
Tel: +46 (0)73-258 81 59, e-post: [email protected]
TO THE EDITORS
About Senzime
Senzime develops and markets CE- and FDA cleared patient monitoring systems driven by unique algorithms and sensors to closely monitor patients under anesthesia. TetraGraph is a system that digitally and continuously measures the degree of neuromuscular blockade in the patient. The goal is improved clinical precision and simplified management in healthcare. By preventing complications and enabling healthcare professionals to follow guidelines and drug recommendations, TetraGraph can contribute to shorten hospital stays and lower healthcare costs. The vision is a world without anesthesia related complications, where everyone wakes up safely after surgery. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North Growth Market (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399, [email protected] is Certified Adviser for Senzime. www.senzime.com